Download
fimmu-12-631139.pdf 1,87MB
WeightNameValue
1000 Titel
  • A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
1000 Autor/in
  1. Triggle, Chris R. |
  2. Bansal, Devendra |
  3. Ding, Hong |
  4. Islam, Md Mazharul |
  5. Farag, Elmoubashar Abu Baker Abd |
  6. Hadi, Hamad Abdel |
  7. Sultan, Ali A. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-26
1000 Erschienen in
1000 Quellenangabe
  • 12:631139
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fimmu.2021.631139 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952616/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • COVID-19 emerged from China in December 2019 and during 2020 spread to every continent including Antarctica. The coronavirus, SARS-CoV-2, has been identified as the causative pathogen, and its spread has stretched the capacities of healthcare systems and negatively affected the global economy. This review provides an update on the virus, including the genome, the risks associated with the emergence of variants, mode of transmission, immune response, COVID-19 in children and the elderly, and advances made to contain, prevent and manage the disease. Although our knowledge of the mechanics of virus transmission and the immune response has been substantially demystified, concerns over reinfection, susceptibility of the elderly and whether asymptomatic children promote transmission remain unanswered. There are also uncertainties about the pathophysiology of COVID-19 and why there are variations in clinical presentations and why some patients suffer from long lasting symptoms—“the long haulers.” To date, there are no significantly effective curative drugs for COVID-19, especially after failure of hydroxychloroquine trials to produce positive results. The RNA polymerase inhibitor, remdesivir, facilitates recovery of severely infected cases but, unlike the anti-inflammatory drug, dexamethasone, does not reduce mortality. However, vaccine development witnessed substantial progress with several being approved in countries around the globe.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal pathophysiology
lokal immune response
lokal transmission
lokal drugs
lokal COVID vaccines
lokal SARS-CoV-2
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/VHJpZ2dsZSwgQ2hyaXMgUi4=|https://frl.publisso.de/adhoc/uri/QmFuc2FsLCBEZXZlbmRyYQ==|https://frl.publisso.de/adhoc/uri/RGluZywgSG9uZw==|https://frl.publisso.de/adhoc/uri/SXNsYW0sIE1kIE1hemhhcnVs|https://frl.publisso.de/adhoc/uri/RmFyYWcsIEVsbW91YmFzaGFyIEFidSBCYWtlciBBYmQ=|https://frl.publisso.de/adhoc/uri/SGFkaSwgSGFtYWQgQWJkZWw=|https://frl.publisso.de/adhoc/uri/U3VsdGFuLCBBbGkgQS4=
1000 Label
1000 Förderer
  1. Weill Cornell Medical College |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. Qatar Distributed eLibrary
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Weill Cornell Medical College |
    1000 Förderprogramm Qatar Distributed eLibrary
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6428048.rdf
1000 Erstellt am 2021-06-08T15:04:29.076+0200
1000 Erstellt von 218
1000 beschreibt frl:6428048
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Tue Jun 29 12:58:15 CEST 2021
1000 Objekt bearb. Tue Jun 29 12:58:02 CEST 2021
1000 Vgl. frl:6428048
1000 Oai Id
  1. oai:frl.publisso.de:frl:6428048 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source